Aug 13, 2025, 08:05
Chris Boshoff: Positive Topline Results for Muscle-Invasive Bladder Cancer
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“People with muscle-invasive bladder cancer not eligible for cisplatin-based chemotherapy have had limited treatment options for too long, and Pfizer is committed to changing that.
The positive topline results from a Phase 3 trial represent important progress for this community. We are grateful to all the participants, researchers, and our partners at Astellas Pharma and Merck who made this study possible.
We’ll continue advancing science to improve outcomes for those impacted by this disease.”
Video attached to the post.
More posts featuring Chris Boshoff on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 22:37
Sep 2, 2025, 22:03
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54